These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18404015)

  • 1. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder.
    Nierenberg AA; Ostacher MJ; Huffman JC; Ametrano RM; Fava M; Perlis RH
    J Occup Environ Med; 2008 Apr; 50(4):428-36. PubMed ID: 18404015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational site-directed pharmacotherapy for major depressive disorder.
    Blier P
    Int J Neuropsychopharmacol; 2014 Jul; 17(7):997-1008. PubMed ID: 23745670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic-based pharmacotherapies for depression.
    Papakostas GI
    Eur Neuropsychopharmacol; 2006 Aug; 16(6):391-402. PubMed ID: 16413172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to the pharmacological management of major depressive disorder.
    Witkin JM; Li X
    Adv Pharmacol; 2009; 57():347-79. PubMed ID: 20230766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criticisms of drugs in early development for the treatment of depression: what can be improved?
    Wang SM; Han C; Pae CU
    Expert Opin Investig Drugs; 2015 Apr; 24(4):445-53. PubMed ID: 25529224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies.
    Ruhé HG; Mason NS; Schene AH
    Mol Psychiatry; 2007 Apr; 12(4):331-59. PubMed ID: 17389902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review.
    Blumberg MJ; Vaccarino SR; McInerney SJ
    J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32726521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical discovery of duloxetine for the treatment of depression.
    Torres-Sanchez S; Perez-Caballero L; Mico JA; Elorza J; Berrocoso E
    Expert Opin Drug Discov; 2012 Aug; 7(8):745-55. PubMed ID: 22680253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in antidepressant therapy in special populations.
    Hayes D
    Am J Manag Care; 2004 Jul; 10(6 Suppl):S179-85. PubMed ID: 15354675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for switching antidepressants to achieve maximum efficacy adolescents.
    Jefferson JW
    J Clin Psychiatry; 2008; 69 Suppl E1():14-8. PubMed ID: 18494539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.